Consistency of Effect with Galcanezumab Across Multiple Cluster Periods in Episodic Cluster Headache
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Key messages
- Post-hoc analysis of two trials investigating galcanezumab 300 mg/month in patients with episodic cluster headache (CH).
- There was good agreement between Patient Global Impression of Improvement (PGI-I) between the 2 CH periods, following the first dose of galcanezumab at month 1.
- Most patients who showed a response in both trials.
Presenting Author
Brian M. Plato, DO
Medical Director, Headache Medicine
NORTON NEUROSCIENCE INSTITUTE
Louisville, Kentucky
Dr. Brian Plato is the medical director of headache medicine with the Norton Neuroscience Institute in Louisville, KY. Dr. Plato received his medical degree from the Chicago College of Osteopathic Medicine. He completed both his internship and residency at the University of Louisville School of Medicine in neurology, where he also served as chief resident and completed a mini-fellowship in headache medicine. Dr. Plato is board-certified in both neurology and headache medicine.
Dr. Plato is vice-president of the Southern Headache Society.
Author disclosures
Brian M. Plato, DO: Allergan (Speaking and Teaching) (Honoraria)Amgen/Novartis (Speaking and Teaching) (Honoraria)Electrocore (Other Activities) (Research Grant or Support)Eli Lilly (Speaking and Teaching) (Honoraria)Teva (Other Activities) (Research Grant or Support)
